George Tidmarsh

Last updated
  1. 1 2 Tidmarsh, G. (1 July 2013). "Linking academia and industry to bring drugs to the clinic: an interview with George Tidmarsh". Disease Models & Mechanisms. 6 (4): 874–876. doi:10.1242/dmm.012997. PMC   3701206 . PMID   23828643.
  2. 1 2 3 Annika Kim, Constantino. "FDA taps biotech industry veteran as RFK Jr.'s top drug regulator". No. 21 July 2025. CNBC. Retrieved 5 November 2025.
  3. ↑ Kartal Allen, Annabel (31 July 2025). "George Tidmarsh to sub in as FDA CBER head following Prasad's shock exit". Pharmaceutical Technology. Retrieved 5 November 2025.
  4. ↑ Weber, Lauren; Roubein, Rachel (August 9, 2025). "FDA regulator reinstalled less than two weeks after White House ouster". thewashingtonpost. Retrieved September 3, 2025.
  5. 1 2 3 Parrish, Meaghan; Gibney, Michael (23 July 2025). "Who is Dr. George Tidmarsh, the new director of CDER?". PharmaVoice. Retrieved 7 November 2025.
  6. ↑ Dunleavy, Kevin (11 July 2022). "Innoviva snaps up La Jolla and its 2 FDA-approved drugs for $149M". Fierce Pharma. Retrieved 7 November 2025.
  7. 1 2 Kansteiner, Frasier (3 November 2025). "CDER chief George Tidmarsh resigns as deleted LinkedIn post prompts Aurinia lawsuit, FDA probe". Fierce Pharma. Retrieved 5 November 2025.
  8. ↑ Council, Stephen (5 November 2025). "Former Stanford professor accused of 'reprehensible' conduct quits top FDA job". SFGate. Retrieved 8 November 2025.
  9. ↑ Herper, Matthew; Lawrence, Lizzie (4 November 2025). "Experts worry FDA's credibility is being shredded by scandal and 'soap opera'". Stat News. Retrieved 5 November 2025.
  10. ↑ Mole, Beth (4 November 2025). "FDA described as a "clown show" amid latest scandal; top drug regulator is out". Ars Technica. Retrieved 5 November 2025.
  11. ↑ Lenzer, Jeanne (7 November 2025). "FDA drug chief resigns amid lawsuit claims of attempting to "extort and solicit a bribe"". theBMJ. Retrieved 11 November 2025.
George Tidmarsh
Director of U.S. Center for Drug Evaluation and Research
In office
July 21, 2025 –November 2, 2025
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.